sur ABIVAX (EPA:ABVX)
Abivax successfully concludes an ADS offer
Abivax announced the full exercise of its option to subscribe to additional American Depositary Shares (ADS). This brings the gross proceeds of the offering to $920 million (€807 million). The biotechnology company, listed on Euronext Paris and Nasdaq, specializes in therapies for chronic inflammatory diseases.
The initial offering comprised 6.4 million ADSs, with an additional 960,000 ADSs to be added after the exercise of the over-allotment option. Settlement of the ADSs is expected to take place on July 6, 2026. Estimated net proceeds will reach approximately $874.1 million (€767.1 million) after deduction of offering-related expenses.
The funds will be used for marketing expenses in the United States and clinical research related to treatments for ulcerative colitis and Crohn's disease.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX